Sofgen Pharma

Sofgen Pharma Equity

The The Equity of Sofgen Pharma (PROCF) as of Nov 7, 2026 is -51.14 M USD. In the previous year, The Equity was 210,000.00 USD — a change of -24,452.86% (lower).

Equity

-51.14 MUSD

YoY

-24,452.86%

Last updated:

In 2024, Sofgen Pharma's equity was -51.14 M USD, a -24,452.86% increase from the 210,000.00 USD equity in the previous year.

The Sofgen Pharma Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2020
-255.50 M USD
Jan 1, 2021
-69.05 M USD
Jan 1, 2022
-36.20 M USD
Jan 1, 2023
210,000.00 USD
Jan 1, 2024
-51.14 M USD
The Sofgen Pharma Equity history
YEAREquityYoY
-51.14 MUSD-24,452.86%
210,000.00USD-100.58%
-36.20 MUSD-47.58%
-69.05 MUSD-72.97%
-255.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Procaps Group SA generates revenue through its five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics sells diabetes solutions, while Farma Procaps markets branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to third-party pharmaceutical companies. Vital Care produces consumer healthcare products, and Clinical Specialties focuses on complex drugs. The company's products include prescription drugs, nutritional supplements like omega 3 fish oils, and high-potency clinical compounds. Farma Procaps targets prescription drug markets in Latin America, selling branded products under its own name. Softi Gel serves third-party pharmaceutical companies by providing development and manufacturing services. Vital Care focuses on consumer healthcare products, and Clinical Specialties develops and markets complex drugs. The primary customers are healthcare providers, pharmaceutical companies, and consumers seeking specialized health solutions. The company's revenue streams are derived from prescription drug sales, contract manufacturing services, and consumer healthcare product distribution. Diabetrics and Clinical Specialties cater to medical professionals with specialized treatments, while Vital Care serves retail consumers through over-the-counter products. Softi Gel's services are contracted by other pharmaceutical firms seeking external development and manufacturing support. Sofgen Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Sofgen Pharma's Equity

Sofgen Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sofgen Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sofgen Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sofgen Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sofgen Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sofgen Pharma stock

The Equity of Sofgen Pharma is -51.14 M USD in 2024.

The Equity of Sofgen Pharma changed from 210,000.00 USD to -51.14 M USD, representing a -24,452.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Sofgen Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sofgen Pharma

All Key Metrics — Sofgen Pharma